Milos Bohonek1,2, Dominik Kutac1,3, Ludmila Landova1, Michaela Koranova1, Eliska Sladkova1, Eva Staskova1, Martin Voldrich4, Tomas Tyll4. 1. Department of Haematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic. 2. Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic. 3. Faculty of Military Health Sciences, University of Defence Hradec Kralove, Hradec Kralove, Czech Republic. 4. Department of Anesthesiology and Intensive Care Medicine, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic.
Abstract
BACKGROUND: The short shelf-life of fresh platelets limits their efficient inventory management and availability during a massive transfusion protocol. Risk of insufficient availability can be mitigated by building an inventory of cryopreserved platelets (CPs). METHODS: A comparative study of fresh apheresis platelets (FAPs) and CPs was performed. Type-O CPs were processed with DMSO frozen at -80°C and reconstituted in thawed AB plasma. All patients enrolled in the study had the following parameters evaluated on admission: vital signs (body temperature, heart rate, mean arterial pressure), blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level, and, in trauma patients, international severity score. Several outcomes were evaluated: 30-day survival, adverse events, quantity of administered blood products, fibrinogen concentrate and thromboxane (TXA), and laboratory parameters after transfusion (blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level). RESULTS: Twenty-five (25) patients in the study group received transfusions totaling 81 units of CPs. Twenty-one (21) patients in the control group received a total of 67 units of FAPs. There were no significant differences in patient characteristics (p > 0.05) between groups. Both groups were comparable in clinical outcomes (30-day survival, administered blood products, fibrinogen concentrate, TXA, and adverse events). Among posttransfusion laboratory parameters, platelet count was higher in the group transfused with FAPs (97.0 ×109 /L) than in the group transfused with CPs (41.5 ×109 /L), p = 0.02025. Other parameters were comparable in both groups. CONCLUSION: The study suggests that CPs are tolerable and a feasible alternative to FAPs. However, larger randomized studies are needed to draw definitive conclusions.
BACKGROUND: The short shelf-life of fresh platelets limits their efficient inventory management and availability during a massive transfusion protocol. Risk of insufficient availability can be mitigated by building an inventory of cryopreserved platelets (CPs). METHODS: A comparative study of fresh apheresis platelets (FAPs) and CPs was performed. Type-O CPs were processed with DMSO frozen at -80°C and reconstituted in thawed AB plasma. All patients enrolled in the study had the following parameters evaluated on admission: vital signs (body temperature, heart rate, mean arterial pressure), blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level, and, in traumapatients, international severity score. Several outcomes were evaluated: 30-day survival, adverse events, quantity of administered blood products, fibrinogen concentrate and thromboxane (TXA), and laboratory parameters after transfusion (blood count, prothrombin time, activated partial thromboplastin time, fibrinogen level). RESULTS: Twenty-five (25) patients in the study group received transfusions totaling 81 units of CPs. Twenty-one (21) patients in the control group received a total of 67 units of FAPs. There were no significant differences in patient characteristics (p > 0.05) between groups. Both groups were comparable in clinical outcomes (30-day survival, administered blood products, fibrinogen concentrate, TXA, and adverse events). Among posttransfusion laboratory parameters, platelet count was higher in the group transfused with FAPs (97.0 ×109 /L) than in the group transfused with CPs (41.5 ×109 /L), p = 0.02025. Other parameters were comparable in both groups. CONCLUSION: The study suggests that CPs are tolerable and a feasible alternative to FAPs. However, larger randomized studies are needed to draw definitive conclusions.
Authors: Péter Jávor; Lilla Hanák; Péter Hegyi; Endre Csonka; Edina Butt; Tamara Horváth; István Góg; Anita Lukacs; Alexandra Soós; Zoltán Rumbus; Eszter Pákai; János Toldi; Petra Hartmann Journal: BMJ Open Date: 2022-10-19 Impact factor: 3.006
Authors: Derek J B Kleinveld; Pieter H Sloos; Femke Noorman; M Adrie W Maas; Jesper Kers; Tim W H Rijnhout; Margreet Zoodsma; Rigo Hoencamp; Markus W Hollmann; Nicole P Juffermans Journal: Transfusion Date: 2020-06-27 Impact factor: 3.157
Authors: Alexander P J Vlaar; Joanna C Dionne; Sanne de Bruin; Marije Wijnberge; S Jorinde Raasveld; Frank E H P van Baarle; Massimo Antonelli; Cecile Aubron; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella C A Müller; Marcus Lance; Nathan D Nielsen; Herbert Schöchl; Beverley J Hunt; Maurizio Cecconi; Simon Oczkowski Journal: Intensive Care Med Date: 2021-10-22 Impact factor: 17.440